Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EIDX

Eidos Therapeutics (EIDX) Stock Price, News & Analysis

Eidos Therapeutics logo

About Eidos Therapeutics Stock (NASDAQ:EIDX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$122.21
$122.21
50-Day Range
$120.98
$128.51
52-Week Range
$28.39
$132.54
Volume
N/A
Average Volume
128,113 shs
Market Capitalization
$4.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Remove Ads
Receive EIDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eidos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EIDX Stock News Headlines

Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
The Anglo File: Game Over for Board Lapses at Eidos
See More Headlines

EIDX Stock Analysis - Frequently Asked Questions

Eidos Therapeutics, Inc. (NASDAQ:EIDX) announced its quarterly earnings results on Thursday, October, 29th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.08. The business had revenue of $0.13 million for the quarter.

Eidos Therapeutics (EIDX) raised $101 million in an initial public offering on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eidos Therapeutics investors own include Bristol-Myers Squibb (BMY), CRISPR Therapeutics (CRSP), Exelixis (EXEL), NVIDIA (NVDA), Micron Technology (MU), Axsome Therapeutics (AXSM) and Occidental Petroleum (OXY).

Company Calendar

Last Earnings
10/29/2020
Today
4/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EIDX
CIK
N/A
Fax
N/A
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$26.69 million
Price / Cash Flow
N/A
Book Value
$4.57 per share
Price / Book
26.74

Miscellaneous

Free Float
N/A
Market Cap
$4.75 billion
Optionable
Not Optionable
Beta
-0.16
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:EIDX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners